Beyond weight management: the medical conditions where GLP-1 therapy has emerging or established evidence.
BMI ≥30 or BMI ≥27 with comorbidity.
Primary FDA-labeled indication for Wegovy and Zepbound.
Insulin resistance with elevated HbA1c.
Original indication for semaglutide (Ozempic) and tirzepatide (Mounjaro).
HbA1c 5.7–6.4% or fasting glucose 100–125 mg/dL.
Weight loss with GLP-1 reduces progression to T2D in trial data.
Polycystic ovary syndrome with insulin resistance component.
Off-label use for weight management in PCOS is increasingly common.
Repeated airway obstruction during sleep, often associated with obesity.
SURMOUNT-OSA showed tirzepatide significantly reduced apnea-hypopnea index in adults with obesity and moderate-severe OSA.
Metabolic dysfunction-associated steatohepatitis.
Emerging GLP-1 evidence for liver outcomes.
Established atherosclerotic cardiovascular disease.
SELECT trial showed semaglutide reduced MACE in adults with overweight/obesity and established CVD without diabetes.
Recurrent episodes of consuming large quantities with loss of control.
Early evidence GLP-1 may reduce binge episodes; not FDA-approved for this indication.
Five minutes. Free. No pressure.